

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/821,670	0/821,670 04/09/2004		Ramani S. Wonderling	IM-5-1	9877	
26949	7590	07/27/2006		EXAMINER		
HESKA C	ORPOR	ATION		MARTINE	L, JAMES	
		ROPERTY DEPT. NTAIN AVE	ART UNIT	PAPER NUMBER		
LOVELAN	D, CO	80538	1634			
				DATE MAILED: 07/27/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

1 1	$\mathcal{P} = \mathcal{O}$	Application No.	Applicant(s)
	Office Action Summany	10/821,670	WONDERLING ET AL.
	Office Action Summary	Examiner	Art Unit
		James Martinell	1634
بن Period for ا	The MAILING DATE of this communication app Reply	pears on the cover sheet with the c	orrespondence address
A SHOP WHICH - Extensic after SI - If NO pe - Failure t Any repl	RTENED STATUTORY PERIOD FOR REPL' EVER IS LONGER, FROM THE MAILING Do ons of time may be available under the provisions of 37 CFR 1.1 K (6) MONTHS from the mailing date of this communication. Friod for reply is specified above, the maximum statutory period to oreply within the set or extended period for reply will, by statute by received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status			•
2a)∐ T 3)∐ S	esponsive to communication(s) filed on $\underline{25 \text{ M}}$ his action is FINAL . 2b) \boxtimes This ince this application is in condition for allowards osed in accordance with the practice under E	s action is non-final. nce except for formal matters, pro	
Disposition	of Claims		
4a 5) □ C 6) □ C 7) □ C 8) □ C Application 9) □ Th 10) □ Th	laim(s) 22-34 and 42-47 is/are pending in the a) Of the above claim(s) is/are withdraw laim(s) is/are allowed. laim(s) 22-25,27-33,43,44,46 and 47 is/are relaim(s) 26,34,42 and 45 is/are objected to. laim(s) are subject to restriction and/or a Papers the specification is objected to by the Examine the drawing(s) filed on is/are: a) accomplicant may not request that any objection to the eplacement drawing sheet(s) including the corrective oath or declaration is objected to by the Examine the oath of th	wn from consideration. ejected. or election requirement. er. epted or b) objected to by the l drawing(s) be held in abeyance. Sec	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority und	der 35 U.S.C. § 119		
12)	cknowledgment is made of a claim for foreign All b) Some * c) None of: Certified copies of the priority document Certified copies of the priority document priority document priority document priority document not copies of the certified copies of the priority document application from the International Bureau the attached detailed Office action for a list	es have been received. Es have been received in Application rity documents have been received (PCT Rule 17.2(a)).	on Noed in this National Stage
2) ☐ Notice o 3) ☑ Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) tion Disclosure Statement(s) (PTO-1449 or PTO/SB/08) lo(s)/Mail Date <u>6/1/04 & 7/26/04</u> .	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	

Application/Control Number: 10/821,670

Art Unit: 1634

Claim 28 is objected to because of the following informalities:

In part (c), "has a nucleic acid sequences" should be changed to "has a nucleic acid sequence".

Appropriate correction is required.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 24, 25, and 27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are vague, indefinite, misdescriptive, and inaccurate.

- (a) The recitation of "at least about" (claim 24(c)) is vague and indefinite. It is noted that 88% is "about" 90% and that 89% is "at least" 88%, but 89% is not "at least" 90%. Thus, it is unclear whether 89% sequence identity is embraced by the claim. The metes and bounds of the claim are unclear.
- (b) The recitation of "having the amino acid sequence of SEQ ID NO: 38 or SEQ ID NO: 43" (claim 25(a) and (b)) is misdescriptive and inaccurate because SEQ ID NOs: 38 and 43 are nucleic acids and not peptides.
- (c) The recitation of "said isolated nucleic acid sequence molecule comprises SEQ ID NO: 38 or SEQ ID NO: 43" (claims 27(c) and 28(c)) is misdescriptive and inaccurate because SEQ ID NOs: 38 and 43 are nucleic acids and not peptides.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly

Art Unit: 1634

owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 22-25, 27-33, 43, 44, 46, and 47 are rejected under 35 U.S.C. 103(a) as being unpatentable over Foss et al (Scand. J. Immunol. 50: 596 (1999) in view of applicants' admitted state of the prior art (*e.g.*, instant application at pages 3-4). Foss et al teaches the construction of an expression vector that contains the coding sequences for porcine p35 and p40 subunit proteins of IL-12 connected by a linker (*e.g.*, see the Abstract, Figure 1B, and page 597). The vector is used to express porcine II-12 *in vivo* and *in vitro* (*e.g.*, see the Abstract and the Discussion section). Applicants acknowledge feline p35 and p40 coding sequences to be old (*e.g.*, see the instant application at pages 3-4). It would have been obvious for one of ordinary skill in the art at the time the invention was made to substitute the admittedly old feline sequences for the porcine sequences of Foss et al in the vector of Foss et al in order to express feline II-12 *in vivo* and *in vitro* in a manner similar to that of Foss et al for the production of porcine IL-12.

Claims 26, 34, 42, and 45 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Martinell whose telephone number is (571) 272-0719.

The examiner works a flexible schedule and can be reached by phone and voice mail.

Alternatively, a request for a return telephone call may be e-mailed to james.martinell@uspto.gov. Since e-mail communications may not be secure, it is suggested that information in such requests be limited to name, phone number, and the best time to return the call.

Application/Control Number: 10/821,670

Art Unit: 1634

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735.

OFFICIAL FAX NUMBER

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Any Official Communication to the USPTO should be faxed to this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

James Martinell, Ph.D. Primary Examiner Art Unit 1634

1/23/06

Page 4